13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839948
Total reported value
$4.2B
$4.2B
36 檔
10.5%
The Q3 2024 SEC filing reveals that TCG Crossover Management, LLC held a total portfolio value of $4.2B, covering 36 public equity positions.
In Q3 2024, TCG Crossover Management, LLC displayed an active expansion posture, initiating 9 new positions and adding to 2 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 11.73% | -0.84% | — | |
| 2 | DYN | Dyne Therapeutics Inc | Stock-Other | 8.07% | +0.07% | — | |
| 3 | COGT | Cogent Biosciences Inc | Stock-Other | 6.37% | -0.93% | — | |
| 4 | ABVX | Abivax Sa-adr | Stock-Other | 5.91% | -1.41% | — | |
| 5 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 4.78% | — | -7.03% | |
| 6 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 4.67% | +0.34% | -7.94% | |
| 7 | SVRA | Savara Inc | Stock-Other | 4.44% | -0.10% | — | |
| 8 | KROS | Keros Therapeutics Inc | Stock-Other | 4.33% | — | — | |
| 9 | XNCR | Xencor Inc | Stock-Other | 4.14% | +0.10% | — | |
| 10 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.96% | -1.07% | — | |
| 11 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.95% | -0.19% | EXIT | |
| 12 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.92% | -0.01% | — | |
| 13 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.92% | -4.87% | EXIT | |
| 14 | TRML | Tourmaline Bio Inc | Stock-Other | 3.22% | — | — | |
| 15 | ✓ | Third Harmonic Bio Inc | Stock-Other | 2.77% | — | — | |
| 16 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 2.58% | — | — | |
| 17 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 2.53% | — | -22.45% | |
| 18 | KURA | Kura Oncology Inc | Stock-Other | 2.36% | — | — | |
| 19 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.35% | — | — | |
| 20 | CMPS | Compass Pathways PLC | Stock-Other | 2.06% | — | — | |
| 21 | IRON | Disc Medicine Inc | Stock-Other | 2.03% | -0.09% | — | |
| 22 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.59% | -1.15% | EXIT | |
| 23 | MBX | Mbx Biosciences Inc | Stock-Other | 1.43% | +0.30% | — | |
| 24 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.27% | +0.22% | — | |
| 25 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 1.19% | — | — | |
| 26 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.79% | -0.64% | — | |
| 27 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.68% | -0.04% | EXIT | |
| 28 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.65% | — | -58.33% | |
| 29 | EYPT | Eyepoint Inc | Stock-Other | 0.62% | — | — | |
| 30 | NKTREUR | Nektar Therapeutics | Stock-Other | 0.44% | — | — | |
| 31 | ✓ | Stock-Other | 0.40% | — | — | ||
| 32 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.39% | +1.02% | — | |
| 33 | KOD | Kodiak Sciences Inc | Stock-Other | 0.22% | -0.23% | +12.02% | |
| 34 | ANTX | An2 Therapeutics Inc | Stock-Other | 0.14% | — | — | |
| 35 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.06% | — | — | |
| 36 | CABA | Cabaletta Bio Inc | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XNCR | Xencor Inc | +4.1% | NEW | New buy |
| 2 | ✓ | Third Harmonic Bio Inc | +2.8% | NEW | New buy |
| 3 | SLNOEUR | Soleno Therapeutics Inc | +2.4% | NEW | New buy |
| 4 | FULC | Fulcrum Therapeutics Inc | +1.6% | NEW | New buy |
| 5 | MBX | Mbx Biosciences Inc | +1.4% | NEW | New buy |
| 6 | AMLX | Amylyx Pharmaceuticals Inc | +1.3% | NEW | New buy |
| 7 | TRML | Tourmaline Bio Inc | +1.2% | — | Unchanged |
| 8 | 260 | Centessa Pharmaceuticals-adr | +1.2% | — | Unchanged |
| 9 | AVU0 | Adverum Biotechnologies Inc | +1.2% | NEW | New buy |
| 10 | GPCR | Structure Therapeutics Inc | +1.1% | +53.05% | Add |
| 11 | VTGN | Vistagen Therapeutics Inc | +0.7% | NEW | New buy |
| 12 | TYRA | Tyra Biosciences Inc | +0.7% | — | Unchanged |
| 13 | EWTX | Edgewise Therapeutics Inc | +0.5% | -7.03% | Trim |
| 14 | AVTX | Avalo Therapeutics Inc | +0.4% | NEW | New buy |
| 15 | COGT | Cogent Biosciences Inc | +0.3% | — | Unchanged |
| 16 | KROS | Keros Therapeutics Inc | +0.1% | — | Unchanged |
| 17 | OCUL | Ocular Therapeutix Inc | +0.1% | — | Unchanged |
| 18 | ✓ | 0% | — | Unchanged | |
| 19 | KOD | Kodiak Sciences Inc | — | +12.02% | Add |
| 20 | VTYXUSD | Ventyx Biosciences Inc | 0% | — | Unchanged |
| 21 | CATBUSD | Astria Therapeutics Inc | 0% | — | Unchanged |
| 22 | CABA | Cabaletta Bio Inc | 0% | — | Unchanged |
| 23 | TRDA | Entrada Therapeutics Inc | -0.1% | — | Unchanged |
| 24 | NKTREUR | Nektar Therapeutics | -0.1% | — | Unchanged |
| 25 | ANTX | An2 Therapeutics Inc | -0.2% | — | Unchanged |
| 26 | EYPT | Eyepoint Inc | -0.2% | — | Unchanged |
| 27 | IRON | Disc Medicine Inc | -0.3% | — | Unchanged |
| 28 | CGON | Cg Oncology Inc | -0.4% | — | Unchanged |
| 29 | CMPS | Compass Pathways PLC | -0.4% | — | Unchanged |
| 30 | CCCC | C4 Therapeutics Inc | -0.6% | EXIT | Sold out |
| 31 | KURA | Kura Oncology Inc | -0.7% | — | Unchanged |
| 32 | SVRA | Savara Inc | -0.8% | — | Unchanged |
| 33 | TARS | Tarsus Pharmaceuticals Inc | -0.9% | -58.33% | Trim |
| 34 | VTGNUSD | Vistagen Therapeutics Inc | -1% | EXIT | Sold out |
| 35 | MLYS | Mineralys Therapeutics Inc | -1.4% | -22.45% | Trim |
| 36 | ADVMCHF | Adverum Biotechnologies Inc | -1.4% | EXIT | Sold out |
| 37 | DYN | Dyne Therapeutics Inc | -1.7% | — | Unchanged |
| 38 | SLN | Silence Therapeutics Plc-adr | -1.9% | -7.94% | Trim |
| 39 | SLNOEUR | Soleno Therapeutics Inc | -2.3% | EXIT | Sold out |
| 40 | ABVX | Abivax Sa-adr | -2.4% | — | Unchanged |
| 41 | MDGL | Madrigal Pharmaceuticals Inc | -4.4% | EXIT | Sold out |
According to official SEC Form 13F filings, TCG Crossover Management, LLC reported a total U.S. public equity portfolio value of $4.2B across 36 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGON, DYN, COGT) accounted for 10.5% of total reported equity market value during Q3 2024.
Top New Position Initiated
XNCR
市值: $48.8M
Top Position Liquidated / Trimmed
MDGL
前期市值: $41.8M
During Q3 2024, TCG Crossover Management, LLC's top holdings by market value included CGON (11.7%)、DYN (8.1%)、COGT (6.4%). The largest single position, CGON, represented 11.7% of total portfolio value.
In Q3 2024, TCG Crossover Management, LLC made 20 total portfolio adjustments, initiating 9 new buys, adding to 2 positions, trimming 4 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.